Literature DB >> 7479582

Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition.

M S Thomsen1, S Loft, D W Roberts, H E Poulsen.   

Abstract

Acetaminophen hepatotoxicity is associated with its biotransformation to the reactive metabolite N-acetyl-p-benzoquinone imine that binds to protein. Two forms of cytochrome P450, CYP2E1 and CYP1A2, have been implicated as primarily responsible for the bioactivation. To determine the relative contributions of these P450's, overnight fasted male NMRI mice were pretreated with 10 ml of 50% v/w propylene glycol/kg or fluvoxamine (10 mg/kg) at -80 and -20 min. relative to acetaminophen dosing to inhibit CYP2E1 and CYP1A2, respectively. Mice were sacrificed at 0.5 or 4 hr after a hepatotoxic dose of acetaminophen (300 mg/kg). Propylene glycol or propylene glycol plus fluvoxamine, but not fluvoxamine alone protected against acetaminophen hepatotoxicity as indicated by abolished increase in serum alanine aminotransferase activity, less depletion of hepatic glutathione and lower liver:body weight ratios. Propylene glycol inhibited the activity of CYP2E1 as indicated by 84% reduction in the clearance of 3 mg/kg dose of chlorzoxazone, whereas fluvoxamine inhibited the activity of CYP1A2 as indicated by 40% reduction in the clearance of a 10 mg/kg dose of caffeine. For this animal model, the data are consistent with the notion that hepatoxicity is associated with bioactivation of acetaminophen by CYP2E1 but not by CYP1A2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479582     DOI: 10.1111/j.1600-0773.1995.tb00168.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  8 in total

1.  Effect of excipients on acetaminophen metabolism and its implications for prevention of liver injury.

Authors:  Michael Ganetsky; Mark Böhlke; Luis Pereira; David Williams; Barbara LeDuc; Shiva Guatam; Steven D Salhanick
Journal:  J Clin Pharmacol       Date:  2013-02-22       Impact factor: 3.126

Review 2.  Acetaminophen hepatotoxicity: An update.

Authors:  C J McClain; S Price; S Barve; R Devalarja; S Shedlofsky
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 4.  Paracetamol, alcohol and the liver.

Authors:  L F Prescott
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 5.  Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens.

Authors:  P Obermayer-Straub; M P Manns
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

6.  Protective effect of chlormethiazole, a sedative, against acetaminophen-induced liver injury in mice.

Authors:  H C Lee; S A Jung; H K Jung; S Y Yi; D Y Kim; I H Moon; S S Park
Journal:  Korean J Intern Med       Date:  1999-07       Impact factor: 2.884

7.  Changes in human hepatic metabolism in steatosis and cirrhosis.

Authors:  Zoe Schofield; Michelle Ac Reed; Philip N Newsome; David H Adams; Ulrich L Günther; Patricia F Lalor
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

8.  25-Hydroxycholesterol 3-Sulfate Recovers Acetaminophen Induced Acute Liver Injury via Stabilizing Mitochondria in Mouse Models.

Authors:  Yaping Wang; William M Pandak; Edward J Lesnefsky; Phillip B Hylemon; Shunlin Ren
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.